X4 PHARMACEUTICALS, INC Adjustments to Additional Paid in Capital, Fair Value
X4 PHARMACEUTICALS, INC (XFOR) reported Adjustments to Additional Paid in Capital, Fair Value of $817.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-17.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket · last filed 2022-03-17
- X4 PHARMACEUTICALS, INC adjustments to additional paid in capital, fair value for the quarter ending 2019-03-31 was $817.00K.
- X4 PHARMACEUTICALS, INC adjustments to additional paid in capital, fair value for fiscal 2019 was $817.00K.
| Period end | Adjustments to Additional Paid in Capital, Fair Value 3 month | Adjustments to Additional Paid in Capital, Fair Value 12 month |
|---|---|---|
| 2019-12-31 | $817.00K 10-K · filed 2022-03-17 | |
| 2019-03-31 | $817.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |